Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnoflorine is a quaternary isoquinoline alkaloid widely distributed in various medicinal plants, including *Magnolia officinalis*, *Phellodendron amurense*, *Tinospora cordifolia*, and *Corydalis* species. It exhibits a broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, neuroprotective, and anti-tumor effects. Mechanistically, magnoflorine has been shown to inhibit the NF-κB and MAPK signaling pathways, suppress ALOX15-mediated ferroptosis, and activate the PI3K/AKT pathway. It is currently being investigated in preclinical models for its potential therapeutic applications in osteoarthritis, cerebral ischemia-reperfusion injury (stroke), coronary heart disease, and exercise-induced fatigue. Additionally, it has shown promise in remodeling lipid metabolism in the tumor microenvironment of prostate cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnoflorine.